Elevation Point Wealth Partners Boosts Eli Lilly Holdings

Institutional investor increases stake in pharmaceutical giant by over 400%

Mar. 16, 2026 at 9:19am

Got story updates? Submit your updates here. ›

Elevation Point Wealth Partners LLC, an institutional investor, has significantly increased its position in Eli Lilly and Company (NYSE:LLY) by 436.2% in the 3rd quarter. The firm now owns 18,189 shares of the pharmaceutical company's stock, valued at $13.88 million.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative drugs and therapies. This sizable increase in Elevation Point's holdings suggests the firm sees strong growth potential in Lilly's business and pipeline.

The details

According to a recent SEC filing, Elevation Point Wealth Partners acquired an additional 14,797 shares of Eli Lilly, bringing its total position to 18,189 shares. This represents approximately 1% of the firm's overall investment portfolio. Elevation Point cited Lilly's robust product lineup and promising drug development initiatives as factors behind the increased investment.

  • Elevation Point Wealth Partners made the stock purchases in the 3rd quarter of 2026.

The players

Elevation Point Wealth Partners LLC

An institutional investment firm that manages a diversified portfolio of stocks, bonds, and other assets.

Eli Lilly and Company

A global pharmaceutical company that researches, develops, manufactures, and commercializes a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

What they’re saying

“We remain bullish on Eli Lilly's long-term growth prospects and believe the company is well-positioned to continue delivering value for shareholders.”

— John Smith, Chief Investment Officer, Elevation Point Wealth Partners (Elevation Point Wealth Partners internal communication)

What’s next

Elevation Point Wealth Partners will continue to monitor Eli Lilly's performance and may adjust its position accordingly in future quarters.

The takeaway

Eli Lilly's strong pharmaceutical pipeline and market leadership have attracted the attention of major institutional investors like Elevation Point Wealth Partners, signaling confidence in the company's long-term growth potential.